Currently, Gary M. Phillips is Chairman-Supervisory Board for Nanobiotix SA and President & Chief Executive Officer for OrphoMed, Inc.

He is also on the board of Aldeyra Therapeutics, Inc., Rheon Medical SA and Helio Vision, Inc.

In the past Dr. Phillips was Executive Chairman for Envisia Therapeutics, Inc., Senior Vice President & President-Autoimmune at Mallinckrodt Plc and Chief Strategy Officer & Executive Vice President at Mallinckrodt Brand Pharmaceuticals LLC (a subsidiary of Mallinckrodt Plc), President at Reckitt Benckiser Pharmaceuticals, Inc., President-U.S. Surgical & Pharmaceuticals at Bausch & Lomb, Inc., Managing Consultant at Towers Perrin, Inc., Executive Director-Strategic Planning at Novartis Pharmaceuticals Corp., Managing Consultant at Towers Watson & Co. and Head-Global Health & Healthcare at Forum Mondial de L'Economie.

He received an MBA from The Wharton School of the University of Pennsylvania, a doctorate from Perelman School of Medicine and an undergraduate degree from The College of Arts & Sciences.